169 related articles for article (PubMed ID: 32041350)
1.
Sarno F; Pepe G; Termolino P; Carafa V; Massaro C; Merciai F; Campiglia P; Nebbioso A; Altucci L
Cells; 2020 Feb; 9(2):. PubMed ID: 32041350
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
3. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
Ishiura M; Kitai Y; Kashiwakura JI; Muromoto R; Toda J; Ichii M; Oritani K; Matsuda T
Biochem Biophys Res Commun; 2021 Jun; 556():185-191. PubMed ID: 33845308
[TBL] [Abstract][Full Text] [Related]
4. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
6. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
7. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
Hjort EE; Huang W; Hu L; Eklund EA
Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL
J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459
[TBL] [Abstract][Full Text] [Related]
9. Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK
Souid S; Najjaa H; Riahi-Chebbi I; Haoues M; Neffati M; Arnault I; Auger J; Karoui H; Essafi M; Essafi-Benkhadir K
Nutr Cancer; 2017 Jan; 69(1):117-130. PubMed ID: 27892697
[TBL] [Abstract][Full Text] [Related]
10. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL signaling: A new STATus in CML.
Fabbro D
Nat Chem Biol; 2012 Feb; 8(3):228-9. PubMed ID: 22337094
[No Abstract] [Full Text] [Related]
12. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
[TBL] [Abstract][Full Text] [Related]
13. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
14. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
Bourgeais J; Ishac N; Medrzycki M; Brachet-Botineau M; Desbourdes L; Gouilleux-Gruart V; Pecnard E; Rouleux-Bonnin F; Gyan E; Domenech J; Mazurier F; Moriggl R; Bunting KD; Herault O; Gouilleux F
Oncotarget; 2017 Jun; 8(26):41876-41889. PubMed ID: 27566554
[TBL] [Abstract][Full Text] [Related]
16. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
17. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
20. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
